Effect of Acute Poly(ADP-ribose) Polymerase Inhibition by 3-AB on Blood-brain Barrier Permeability and Edema Formation After Focal Traumatic Brain Injury in Rats
Overview
Neurology
Authors
Affiliations
Recent evidence supports a crucial role for matrix metalloproteinase-9 (MMP-9) in blood-brain barrier (BBB) disruption and vasogenic edema formation after traumatic brain injury (TBI). Although the exact causes of MMP-9 upregulation after TBI are not fully understood, several arguments suggest a contribution of the enzyme poly(ADP-ribose)polymerase (PARP) in the neuroinflammatory response leading to MMP-9 activation. The objectives of this study were to evaluate the effect of PARP inhibition by 3-aminobenzamide (3-AB) (1) on MMP-9 upregulation and BBB integrity, (2) on edema formation as assessed by magnetic resonance imaging (MRI), (3) on neuron survival as assessed by (1)H magnetic resonance spectroscopy ((1)H-MRS), and (4) on neurological deficits at the acute phase of TBI. Western blots and zymograms showed blunting of MMP-9 upregulation 6 h after TBI. BBB permeability was decreased at the same time point in 3-AB-treated rats compared to vehicle-treated rats. Cerebral MRI showed less "free" water in 3-AB-treated than in vehicle-treated rats 6 h after TBI. MRI findings 24 h after TBI indicated predominant cytotoxic edema, and at this time point no significant differences were found between 3-AB- and vehicle-treated rats with regard to MMP-9 upregulation, BBB permeability, or MRI changes. At both 6 and 24 h, neurological function was better in the 3-AB-treated than in the vehicle-treated rats. These data suggest that PARP inhibition by 3-AB protected the BBB against hyperpermeability induced by MMP-9 upregulation, thereby decreasing vasogenic edema formation 6 h after TBI. Furthermore, our data confirm the neuroprotective effect of 3-AB at the very acute phase of TBI.
Glitches in the brain: the dangerous relationship between radiotherapy and brain fog.
Marino N, Bedeschi M, Vaccari M, Cambiaghi M, Tesei A Front Cell Neurosci. 2024; 18:1328361.
PMID: 38515789 PMC: 10956129. DOI: 10.3389/fncel.2024.1328361.
Endothelial Dysfunction in Neurodegenerative Diseases.
Fang Y, Hsieh Y, Hu C, Tu Y Int J Mol Sci. 2023; 24(3).
PMID: 36769234 PMC: 9918222. DOI: 10.3390/ijms24032909.
Gutierrez-Quintana R, Walker D, Williams K, Forster D, Chalmers A Neurooncol Adv. 2022; 4(1):vdab190.
PMID: 35118383 PMC: 8807076. DOI: 10.1093/noajnl/vdab190.
Emerging role of PARP-1 and PARthanatos in ischemic stroke.
Liu S, Luo W, Wang Y J Neurochem. 2021; 160(1):74-87.
PMID: 34241907 PMC: 9010225. DOI: 10.1111/jnc.15464.
Wang J, Ma C, Zhu J, Rao G, Li H Dose Response. 2020; 18(1):1559325819901242.
PMID: 32030092 PMC: 6977239. DOI: 10.1177/1559325819901242.